Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2024/04/065433
CTRI/2024/04/065433
Not yet recruiting
Phase 3

An Interventional Prospective Clinical Study To Assess The Role Of Indicated Homoeopathic Medicines In The Management Of Gout - nil

Dr M P K Homoeopathic Medical College Hospital and Research Centre0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Dr M P K Homoeopathic Medical College Hospital and Research Centre
Status
Not yet recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Dr M P K Homoeopathic Medical College Hospital and Research Centre

Eligibility Criteria

Inclusion Criteria

  • •As per the following list of clinical features shown by the patient If four symptoms should be found out of eight symptoms the cases shall be enrolled for the study
  • •1 Serum urate level more than 6mg/dl in women and more than 7mg/dl in men
  • •2 More than one attack of acute arthritis maximum inflammation developed in one day
  • •3 Redness observed in joints
  • •4 Unilateral first MTP joint painful or swollen
  • •5 Unilateral tarsal joint attack
  • •6 Asymmetrical swelling within a joint
  • •7 Tophus or Subcortical cysts without erosion on x ray
  • •8 History of complete termination of an attack after treatment
  • •Pre diagnosed cases of gout patients who are seeking for homoeopathic treatment

Exclusion Criteria

  • •1 Pregnant women and lactating women are not included
  • •2 Patient who need emergency treatment
  • •3 Patient with severe systemic illness
  • •4 Patients who are not willing to give written consent for the study

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
A Clinical Study to evaluate the effectiveness of Jolly Tulsi 51 drops for Boosting Immune system and Detoxification in healthy subjects.
CTRI/2018/02/012126Jolly Health Care30
Recruiting
Not Applicable
Prospective interventional clinical study to evaluate the efficacy and safety of atezolizumab plus bevacizumab in combination with carbon ion radiotherapy for unresectable hepatocellular carcinomahepatocellular carcinoma
JPRN-UMIN000051549Yamagata University20
Completed
Phase 3
Effectiveness of Homoeopathic medicines in Hypertrophied Adenoid
CTRI/2019/11/022163DR SHAREENA C P30
Recruiting
Phase 1
REIMAGINE – Real-world EvaluatIon of Mepolizumab in severe Asthma achievinG on treatment clinIcal remissioN, a prospEctive study.severe asthmaMedDRA version: 21.1Level: LLTClassification code: 10068462Term: Eosinophilic asthma Class: 10038738Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
CTIS2023-509026-21-00Glaxosmithkline Research & Development Limited336
Not yet recruiting
Phase 2
A clinical trial to assess efficacy of Angiotensin Receptor Nephrilysin Inhibitor (Sacubitril/Valsartan) in right ventricular systolic dysfunction with normal LV functionâ??
CTRI/2023/01/049280MDM hospitalDr SN Medical College